Finance

Lists
CAI:NASDAQ
Caris Life Sciences Inc
$25.32
+2.10%
(+0.52) 1D
$25.27
-0.20% (-0.050)
After hours
Closed: Sep 3, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CAI...
Open
$24.94
High
$25.34
Low
$23.62
Mkt. cap
7.16B
Avg. vol.
5.35M
Volume
0.00
P/E ratio
69.01
52-wk high
$36.79
52-wk low
$14.19
EPS
$0.37
Shares outstanding
282.60M
No. of employees
2K
Open
$24.94
High
$25.34
Low
$23.62
Mkt. cap
7.16B
Avg. vol.
5.35M
Volume
0.00
P/E ratio
69.01
52-wk high
$36.79
52-wk low
$14.19
EPS
$0.37
Shares outstanding
282.60M
No. of employees
2K
News stories
From web sources and news partners
About Caris Life Sciences Inc
CEO-
Employees1.85K
Founded2008
HeadquartersIrving, Texas, United States
SectorBiotechnology
Websitecarislifesciences.com
Analyst ratings
Based on 8 analysts giving stock ratings to CAI in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CAI in the last 3 months.
Highest
Current $25.32
$33.00 (+30.33%)
Average
$26.29 (+3.83%)
Lowest
$21.00 (-17.06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mark Massaro
BTIG
Buy
Reiterated
$33.00
+30.3%
08/07/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
-
-
08/06/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$25.00
-1.3%
08/06/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$26.00
+2.7%
08/06/2026
David Westenberg
Piper Sandler
Hold
Maintained
$21.00
-17.1%
08/06/2026
Kyle Mikson CFA
Canaccord Genuity
Hold
Reiterated
$22.00
-13.1%
08/06/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$30.00
+18.5%
07/15/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
$27.00
+6.6%
07/01/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
06/01/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$36.00
+42.2%
05/11/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$22.00
-13.1%
05/08/2026
Patrick B Donnelly
Citi
Buy
Maintained
$28.00
+10.6%
05/08/2026
Tycho Peterson
Jefferies
Buy
Initiated
$28.00
+10.6%
04/12/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
/ $0.01
0.00%miss
Revenue / Est. (USD)
263.71M / 238.08M
+10.77%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
216.83M
292.89M
216.17M
263.71M
Cost of goods sold
69.33M
70.10M
74.83M
84.12M
Cost of revenue
69.33M
70.10M
74.83M
84.12M
Research and development expenses
21.62M
29.82M
31.32M
32.36M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
93.24M
104.55M
104.75M
120.31M
Operating expense
114.86M
134.37M
136.07M
152.67M
Total operating expenses
184.19M
204.48M
210.89M
236.79M
Operating income
32.64M
88.41M
5.28M
26.93M
Other non operating income
-2.17M
-148.00K
49.00K
101.00K
EBT including unusual items
24.32M
81.96M
-644.00K
-614.00K
EBT excluding unusual items
24.32M
83.92M
-644.00K
24.62M
Income tax expense
-
-
-134.00K
23.00K
Effective tax rate
-
-
20.81%
-3.75%
Other operating expenses
-
-
-
-
Net income
24.32M
81.96M
-510.00K
-637.00K
Net profit margin
11.22%
27.98%
-0.24%
-0.24%
Earnings per share
0.08
0.28
-
-
Interest and investment income
7.36M
7.02M
6.83M
6.82M
Interest expense
-13.51M
-11.36M
-12.81M
-9.23M
Net interest expenses
-6.15M
-4.34M
-5.98M
-2.41M
Depreciation and amortization charges
-
-
-
-
EBITDA
37.51M
92.70M
10.35M
33.46M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps